Bimekizumab treatment completely reversed the levels of cytokines/chemokines, anti‐microbial peptides, or proliferation‐related molecules, such as CXCL8, CCL20, IL‐17A, IL‐17F, IL‐17C, keratin 16, IL‐36γ, DEFB4, or S100A7, in psoriasis lesional skin to the levels of non‐lesional skin.13 This evidence concerns the gene IL17C and psoriasis.